We are live on ! Find out more
RCUS icon

Arcus Biosciences

78 hedge funds and large institutions have $210M invested in Arcus Biosciences in 2019 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 27 increasing their positions, 12 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

533% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 3

125% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 12

22% more funds holding

Funds holding: 6478 (+14)

1.44% more ownership

Funds ownership: 57.92%59.37% (+1.4%)

35% less capital invested

Capital invested by funds: $322M → $210M (-$112M)

40% less funds holding in top 10

Funds holding in top 10: 53 (-2)

Holders
78
Holders Change
+14
Holders Change %
+21.88%
% of All Funds
1.69%
Holding in Top 10
3
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-40%
% of All Funds
0.07%
New
19
Increased
27
Reduced
12
Closed
3
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
AC
51
Athanor Capital
New York
$126K +$159K +15,900 New
MIM
52
MetLife Investment Management
New Jersey
$124K
CS
53
Credit Suisse
Switzerland
$122K -$28.4K -2,838 -16%
Susquehanna International Group
54
Susquehanna International Group
Pennsylvania
$119K +$149K +14,921 New
VOYA Investment Management
55
VOYA Investment Management
Georgia
$118K +$19.3K +1,923 +15%
California Public Employees Retirement System
56
California Public Employees Retirement System
California
$113K +$32K +3,200 +29%
ECM
57
ExodusPoint Capital Management
New York
$102K +$128K +12,784 New
MLICM
58
Metropolitan Life Insurance Company (MetLife)
New York
$91.8K +$14.2K +1,421 +14%
Citigroup
59
Citigroup
New York
$88K -$2.32K -232 -2%
Federated Hermes
60
Federated Hermes
Pennsylvania
$53K +$8.41K +840 +15%
Legal & General Group
61
Legal & General Group
United Kingdom
$47K
UBS Group
62
UBS Group
Switzerland
$46K +$57.8K +5,775 New
BNP Paribas Financial Markets
63
BNP Paribas Financial Markets
France
$41K -$13.7K -1,370 -21%
Canada Life
64
Canada Life
Manitoba, Canada
$39K
AG
65
Aperio Group
California
$32K +$40K +3,999 New
US Bancorp
66
US Bancorp
Minnesota
$23K
Bank of Montreal
67
Bank of Montreal
Ontario, Canada
$21K -$93.3K -9,322 -78%
AIP
68
Ameritas Investment Partners
Nebraska
$20K
PCM
69
Prelude Capital Management
New York
$17K +$22K +2,198 New
Royal Bank of Canada
70
Royal Bank of Canada
Ontario, Canada
$13K +$6.01K +600 +60%
PAM
71
Panagora Asset Management
Massachusetts
$11K +$14.3K +1,426 New
LTFS
72
Ladenburg Thalmann Financial Services
Florida
$6K
MAM
73
Meeder Asset Management
Ohio
$5K +$2.97K +297 +87%
PA
74
Parallel Advisors
California
$5K +$6.26K +625 New
IUHSA
75
Itau Unibanco Holding S.A.
Brazil
$4K -$3.71K -371 -44%

RCUS Hedge Fund Activity: Q2 2019 in Review

78 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Arcus Biosciences (RCUS) for Q2 2019, worth a combined $210M — down 35% from $322M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new RCUS positions and 3 closed out — a net gain of 16 holders — while 27 added to existing stakes and 12 trimmed.

The largest buyer was BVF Inc, adding an estimated $7.26M. The largest seller was Wellington Management Group, cutting an estimated $16.1M.

  • 78 institutional investors held Arcus Biosciences (RCUS) as of Q2 2019, up from 64 in Q1 2019.
  • Funds reported $210M of Arcus Biosciences stock for Q2 2019, down 35% quarter-over-quarter.
  • 19 funds opened new Arcus Biosciences positions in Q2 2019 and 3 closed out, a net change of +16 holders.
  • The largest Arcus Biosciences buyer in Q2 2019 was BVF Inc, an estimated $7.26M added.
  • The largest Arcus Biosciences seller in Q2 2019 was Wellington Management Group, an estimated $16.1M sold.

Based on aggregated 13F filings for Q2 2019.